Early metabolic response evaluation after stereotactic radiotherapy for lung cancer: pilot experience with 18F-fluorodeoxyglucose positron emission tomography-computed tomography

M Dahele; M Freeman; S Pearson; A Brade; B C J Cho; A Hope; K Franks; T Purdie; J P Bissonnette; D A Jaffray; A Bezjak; A Sun

doi:10.1016/j.clon.2010.11.009

Early metabolic response evaluation after stereotactic radiotherapy for lung cancer: pilot experience with 18F-fluorodeoxyglucose positron emission tomography-computed tomography

Clin Oncol (R Coll Radiol). 2011 Jun;23(5):359-63. doi: 10.1016/j.clon.2010.11.009. Epub 2010 Dec 30.

Authors

M Dahele¹, M Freeman, S Pearson, A Brade, B C J Cho, A Hope, K Franks, T Purdie, J P Bissonnette, D A Jaffray, A Bezjak, A Sun

Affiliation

¹ Radiation Medicine Program, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ontario, Canada.

PMID: 21194908
DOI: 10.1016/j.clon.2010.11.009

Abstract

The early response of lung tumours to stereotactic radiotherapy was prospectively evaluated with 18F-fluorodeoxyglucose positron emission tomography-computed tomography. Three months after treatment, the maximum standardised uptake value and the tumour diameter fell by 64 and 30%, respectively. This imaging strategy therefore remains under ongoing evaluation with the aim of identifying predictive and prognostic factors.

Publication types

Evaluation Study
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung / surgery
Female
Fluorodeoxyglucose F18
Humans
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / surgery*
Male
Middle Aged
Pilot Projects
Positron-Emission Tomography / methods*
Radiopharmaceuticals
Radiosurgery*
Tomography, X-Ray Computed / methods*

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18